NFKB1 and central nervous system cancer: Notably, no changes in the amount of phosphorylation of EGFR or NF-kB were observed in TMZ-treated SVZ-EGFRvIII tumors compared to controls (Supplementary Figure 7B), reinforcing the lack of response of these gliomas to the drug.